SCHEMBL5037522

SCHEMBL5037522

COCC1CCCN1c1cc(C)nc2cc(OCc3ccccc3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.42
MCHR1 Q99705 3/20 0.42
CHRNB2 P17787 1/20 0.40
CHRNA5 P30532 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA4 P43681 1/20 0.40
SPHK2 Q9NRA0 3/20 0.40
SPHK1 Q9NYA1 2/20 0.40
ADORA2A P29274 1/20 0.39
DYRK1A Q13627 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037521 1.00 KCNH2 (0.42) KCNH2MCHR1CHRNB2CHRNA5CHRNA7
SCHEMBL5033251 0.90 SPHK2 (0.49) MCHR1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL5033262 0.90 SPHK2 (0.49) MCHR1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL5035795 0.89 SPHK2 (0.44) KCNH2SPHK2CYP3A4
SCHEMBL5037398 0.89 SPHK2 (0.44) KCNH2SPHK2CYP3A4
SCHEMBL5035796 0.89 SPHK2 (0.44) KCNH2SPHK2CYP3A4
SCHEMBL5040496 0.86 ADORA2A (0.39) CHRNB2CHRNA4ADORA2A
SCHEMBL6369357 0.86 ADORA2A (0.39) CHRNB2CHRNA4ADORA2A
Hydrochloric Acid SCHEMBL6369450 0.85 MAOA (0.39) CHRNB2CHRNA4ADORA2A
Hydrochloric Acid SCHEMBL5040540 0.85 MAOA (0.39) CHRNB2CHRNA4ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395564-B1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-20050049413-A1 Quinoline derivatives MUELLER WERNER (CH) 2005-03-03 US disclosed
US-6818767-B2 NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY HOFFMANN-LA ROCHE INC. 2004-11-16 US disclosed
US-20020198194-A1 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198194-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R KCNH2 3289/4885MCHR1 95/4885CHRNB2 2514/4885
US-20050049413-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R KCNH2 3289/4885MCHR1 95/4885CHRNB2 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.